Lilly Surpasses United Way 2010 Campaign Goal

Company's employees, retirees, Foundation commit a total of $11.6 million

INDIANAPOLIS, Nov. 4, 2010 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) Chairman, President and Chief Executive Officer John Lechleiter Ph.D. today presented an $11.6 million check to the United Way.  The check represents the contributions of Lilly's U.S. employees and retirees and a matching gift amount from the Lilly Foundation. The funds were raised for the Central Indiana chapter and other United Way chapters' 2010 fundraising campaigns. Lilly's gift locally represents nearly 25 percent of the United Way of Central Indiana's 2010 annual campaign goal.  

"Lilly is proud to support an incredible community partnership in our work with the United Way and all of its agencies," said Lechleiter.  "It is clear that together, Lilly and the United Way are making a real difference; bringing positive change to our local communities, one person, one family, one neighborhood at a time."

Lilly's annual United Way campaign raised $100,000 above the 2010 goal of $11.5 million.  Lilly recognized some 200 volunteers at a luncheon held at the Baxter YMCA.

"Lilly employees and retirees have unselfishly given their leadership, time, and money, year after year," Lechleiter noted.  "Their support has been especially needed in this tough economic climate, and I deeply appreciate their generosity."

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

SOURCE Eli Lilly and Company

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.